Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Karyopharm Expects Preliminary Unaudited Full Year 2023 Total Revenue Of ~$146M vs $150.03M Est., Expects Prelim Q4 Revenue $33.6M vs $37.64M Est.

Author: Benzinga Newsdesk | January 08, 2024 09:59am

Posted In: KPTI